Price
No data yet.
Social Signal Score
Revenue
$3.0KCompany Profile
- CEO
- Frank D. Heuszel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Beta
- 2.76
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 6.78
Financials
Revenue
$3.0K-94.0%Net Income
$-699.0KEBITDA
$-418.0KFree Cash Flow
$470.0KEPS (diluted)
$-0.01Shares Outstanding (diluted)
107.82M+837.3%Operating Expenses
$353.0KCash & Debt
$10.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $32.0K | $-11.84M | $-0.38 |
| 2024 | $0.00 | $-24.71M | $-0.01 |
| 2023 | $0.00 | $-4.34M | $-0.07 |
| 2022 | $50.0K | $-7.05M | $-0.61 |
| 2021 | $50.0K | $-7.05M | $-0.61 |
| 2020 | $0.00 | $-597.3K | $-0.05 |
Valuation
IBOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·6h ago·Neutral
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited) HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “Company” or “Impact”) dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would rece…
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley's Ltd. HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the “Company”) today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock"). The reverse stock split will become effective at 12:…
View source ↗
Insider trading
Open-market buys and sells by IBO officers and directors.
- Bought
- $161k
- Sold
- $7.0m
8 trades
30 trades
- Macko Todd Dsold
- Macko Todd Dsold
- Grady Jasonsold
- Dss, Inc.sold
- Dss, Inc.sold
- Dss, Inc.sold
- Dss, Inc.sold
- Dss, Inc.sold
13 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IBO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.